Compare UNB & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | ALDX |
|---|---|---|
| Founded | 1891 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 101.1M |
| IPO Year | 1999 | 2014 |
| Metric | UNB | ALDX |
|---|---|---|
| Price | $23.26 | $1.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 20.2K | ★ 910.3K |
| Earning Date | 04-15-2026 | 05-01-2026 |
| Dividend Yield | ★ 5.76% | N/A |
| EPS Growth | 25.52 | ★ 40.43 |
| EPS | ★ 0.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.65 | $1.07 |
| 52 Week High | $29.49 | $6.18 |
| Indicator | UNB | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 45.34 |
| Support Level | $23.06 | $1.49 |
| Resistance Level | $24.77 | $1.88 |
| Average True Range (ATR) | 0.53 | 0.13 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 23.19 | 32.94 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.